A Phase 1/2a study of subretinal administration of OpCT-001 photoreceptor precursor cells derived from iPSCs in patients with primary photoreceptor disease
Research Grant
Awarded By
BlueRock Therapeutics LP
Start Date
February 3, 2025
End Date
July 16, 2029
Awarded By
BlueRock Therapeutics LP
Start Date
February 3, 2025
End Date
July 16, 2029